Abstract
Cystic fibrosis (CF) is a hereditary disease caused by mutations in the gene encoding the chloride channel “cystic fibrosis transmembrane conductance regulator” (CFTR). The lack of functional CFTR in CF airways leads to impaired ion and fluid homeostasis of the fluid layer which lines the airway surfaces (ASL). The ASL is important for proper ciliary beat and clearance of mucus from the airways. According to the “low volume hypothesis”, CF airway epithelia hyperabsorb sodium via the epithelial sodium channel (ENaC). Although the contribution of ENaC to CF pathogenesis is still under debate, there is convincing data demonstrating that re-hydration of the ASL might improve mucociliary clearance in CF patients. ASL re-hydration might, amongst other things, be achieved by a block of airway transepithelial sodium absorption with inhibitors of ENaC. This mini-review article describes the role of ENaC in ASL fluid homeostasis and rehydration, and summarizes the current state of the art in the discovery and establishment of compounds which inhibit ENaC activity and may represent pharmacological tools for the treatment of CF.
Keywords: Airway surface liquid, amiloride, CFTR, cystic fibrosis, ENaC, inhibitor, sodium transport.
Current Molecular Pharmacology
Title:ENaC Inhibitors and Airway Re-hydration in Cystic Fibrosis: State of the Art
Volume: 6
Author(s): Mike Althaus
Affiliation:
Keywords: Airway surface liquid, amiloride, CFTR, cystic fibrosis, ENaC, inhibitor, sodium transport.
Abstract: Cystic fibrosis (CF) is a hereditary disease caused by mutations in the gene encoding the chloride channel “cystic fibrosis transmembrane conductance regulator” (CFTR). The lack of functional CFTR in CF airways leads to impaired ion and fluid homeostasis of the fluid layer which lines the airway surfaces (ASL). The ASL is important for proper ciliary beat and clearance of mucus from the airways. According to the “low volume hypothesis”, CF airway epithelia hyperabsorb sodium via the epithelial sodium channel (ENaC). Although the contribution of ENaC to CF pathogenesis is still under debate, there is convincing data demonstrating that re-hydration of the ASL might improve mucociliary clearance in CF patients. ASL re-hydration might, amongst other things, be achieved by a block of airway transepithelial sodium absorption with inhibitors of ENaC. This mini-review article describes the role of ENaC in ASL fluid homeostasis and rehydration, and summarizes the current state of the art in the discovery and establishment of compounds which inhibit ENaC activity and may represent pharmacological tools for the treatment of CF.
Export Options
About this article
Cite this article as:
Althaus Mike, ENaC Inhibitors and Airway Re-hydration in Cystic Fibrosis: State of the Art, Current Molecular Pharmacology 2013; 6 (1) . https://dx.doi.org/10.2174/18744672112059990025
DOI https://dx.doi.org/10.2174/18744672112059990025 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rosuvastatin Induced Rhabdomyolysis in a Low Risk Patient: A Case Report and Review of the Literature
Current Clinical Pharmacology Zolpidem Therapy for Movement Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Analysis of Homocysteine in Plasma of Rats Exposed to High-fat Diet and Chronic Unpredictable Mild Stress by LC/ESI-MS/MS
Current Analytical Chemistry Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity
Current Neuropharmacology Understanding the Binding Mechanism of Antagonist (AZD3293) Against BACE-1: Molecular Insights into Alzheimer’s Drug Discovery
Letters in Drug Design & Discovery Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Structure, Substrate Complexation and Reaction Mechanism of Bacterial Asparaginases
Current Chemical Biology Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline
Current Medicinal Chemistry In Vivo Bioluminescence Imaging to Assess Pancreatic Islets
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Clearance of Beta-Amyloid in the Brain
Current Medicinal Chemistry Structure-Function Relationships of Plasminogen Activator Inhibitor-1 and Its Potential as a Therapeutic Agent
Current Drug Targets Recent Structural and Computational Insights into Conformational Diseases
Current Medicinal Chemistry Purification and Properties of β-Alanine Synthase from Calf Liver
Protein & Peptide Letters Clinical and Genetic Aspects of the Joubert Syndrome: a Disorder Characterised by Cerebellar Vermian Hypoplasia and Accompanying Brainstem Malformations
Current Genomics Ion Channels and Epilepsy
Current Pharmaceutical Design Aminergic Control and Modulation of Honeybee Behaviour
Current Neuropharmacology